EGF targeted fluorescence molecular tomography as a predictor of PDT outcomes in pancreas cancer models

Kimberley S. Samkoe; Scott C. Davis; Subhadra Srinivasan; Martin E. Isabelle; Julia O'Hara; Tayyaba Hasan; Brian W. Pogue

doi:10.1117/12.842934

2 March 2010 EGF targeted fluorescence molecular tomography as a predictor of PDT outcomes in pancreas cancer models

Kimberley S. Samkoe, Scott C. Davis, Subhadra Srinivasan, Martin E. Isabelle, Julia O'Hara, Tayyaba Hasan, Brian W. Pogue

Author Affiliations +

Proceedings Volume 7551, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XIX; 75510Q (2010) https://doi.org/10.1117/12.842934
Event: SPIE BiOS, 2010, San Francisco, California, United States

Abstract

Verteporfin photodynamic therapy (PDT) is a promising adjuvant therapy for pancreas cancer and investigations for its use are currently underway in both orthotopic xenograft mouse models and in human clinical trials. The mouse models have been studied extensively using magnetic resonance (MR) imaging as a measure of surrogate response to verteporfin PDT and it was found that tumor lines with different levels of aggression respond with varying levels to PDT. MR imaging was successful in determining the necrotic volume caused by PDT but there was difficultly in distinguishing inflamed tissues and regions of surviving tumor. In order to understand the molecular changes within the tumor immediately post-PDT we propose the implementation of MR-guided fluorescence molecular tomography (FMT) in conjunction with an exogenously administered fluorescently labeled epidermal growth factor (EGF-IRDye800CW, LI-COR Biosciences). We have previously shown that MR-guided FMT is feasible in the mouse abdomen when multiple regions of fluorescence are considered from contributing internal organs. In this case the highly aggressive AsPC-1 (+EGFR) orthotopic tumor was implanted in SCID mice, interstitial verteporfin PDT (1mg/kg, 20J/cm) was performed when the tumor reached ~60mm³ and both tumor volume and EGF binding were followed with MR-guided FMT.

Citation Download Citation

Kimberley S. Samkoe, Scott C. Davis, Subhadra Srinivasan, Martin E. Isabelle, Julia O'Hara, Tayyaba Hasan, and Brian W. Pogue "EGF targeted fluorescence molecular tomography as a predictor of PDT outcomes in pancreas cancer models", Proc. SPIE 7551, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XIX, 75510Q (2 March 2010); https://doi.org/10.1117/12.842934

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available